At Digestive Disease Week® (DDW), a global gathering for health care professionals, gastroenterology clinicians, researchers and academics, an abstract presented by Probi® AB will showcase findings from a market-first synbiotic study conducted in collaboration with Clasado Biosciences.

The study abstract, “A New Synbiotic Increases Production of Lactate and Butyrate Due to Synergism Between a Galactooligosaccharide and a Two-Strain Probiotic,” will be presented by Dr. Gunilla Önning, Senior Science Manager at Probi AB, revealing promising insights into how synbiotics could guide the future of gut-mediated health.

Digestive Disease Week takes place 18-21 May 2024, in Washington DC, United States, alongside a digital edition. The event aims to push the frontiers of gut health knowledge through collaboration, centring around the latest studies and evidence in gut health science. As part of the event, notable studies and research projects are presented, giving attendees a closer look at the latest scientific understanding of gastrointestinal health.

The synbiotic study to be presented at DDW investigates the synergistic potential of combining Clasado’s Bimuno® GOS prebiotic galactooligosaccharide ingredient with two probiotic strains, Probi’s L. plantarum HEAL9 and L. paracasei 8700:2. Using a short-term ex vivo model of colonic fermentation, the research team assessed microbial metabolic activity and bacterial community composition.

The results indicate a significant increase in lactate and butyrate production. Of particular note, the synergistic effect is among the first to be evidenced in a commercially available synbiotic concept, marking a turnkey moment in the growth of the emerging synbiotic product market. Alongside the increase in gut and immune health-supporting lactate and butyrate and proliferation of beneficial bacteria through the prebiotic element, the results indicate good tolerability with low gas production, suggesting high versatility for product developers.

Dr. Lucien Harthoorn, R&D Director at Clasado and Lead Author of the study, said: “We are delighted that Dr. Önning of Probi, our collaborating partner in this study, is presenting an abstract at DDW. As well as showcasing the latest groundbreaking research, it’s a fantastic event for understanding the promising future of nutrition in gut health / health care. In our case, the study shows the first scientifically evidenced synergistic effect in a commercially available synbiotic concept. The results have helped us to create a ‘plug in and play’ synbiotic solution that makes product development easier for formulators, and that consumers can trust.”

Dr Önning added: “We are thrilled to present the findings of our ground-breaking study at Digestive Disease Week 2024, offering a unique opportunity for us to connect and engage directly with fellow scientists, healthcare professionals, and academics. By sharing our findings on the synergistic potential of synbiotics, we are illuminating an exciting path forward in gut health, and all the further wellness advantages that this brings. What’s more, it underlines our commitment to advancing digestive health solutions and fostering collaborative efforts within the scientific community.

To learn more about DDW or to register for attendance, please click here.

For more information about the study, please visit clasado.com/synbiotics-with-bimuno-gos.

For more information about Probi, please visit https://www.probi.com